Emyria and UWA expand unique MDMA-inspired analogue library
Released
Released
Announcement PDF
ASX Announcement
18 Oct 2022
Emyria and UWA expand unique MDMA-inspired analogue library
HIGHLIGHTS
Emyria, and partner the University of Western Australia, have shipped their fourth batch of
14 unique MDMA analogues for safety screening with Eurofins (EPA:ERF)
Unique library now exceeds 140 proprietary, neurologically active compounds
In addition, an initial priority set of 5 compounds has been sent to PsychoGenics in the
USA to commence advanced preclinical screening (See ASX release 19 Sep 2022)
Additional metabolic studies have also commenced with an Australian CRO to help
evaluate the half-lives of a priority set of compounds in mice, rat and human liver cells
A recording of a recent webinar outlining the MDMA-inspired drug discovery program is
available here: https://investorhub.emyria.com/ (See ASX release 13 Oct 2022)
Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech focussed on
neuroscience and mental health, is pleased to announce positive progress of its preclinical
MDMA-inspired drug discovery program with partner, the University of Western Australia and
led by medicinal chemistry expert, Dr Matt Piggott.
Emyria and UWA have been actively growing and screening a unique drug-discovery
pipeline of novel MDMA analogues to identify new chemical entities and drug candidates
with the potential to address major unmet needs in mental health and neurological
disorders. Emyria previously secured exclusive rights to all MDMA-like compounds created
under the partnership with Prof. Piggott and UWA. (See ASX announcement 05 Aug 2021)
Additional compound synthesis and screening is ongoing and a fourth batch of 14 unique
compounds, inspired by previous screening results, was recently prepared and shipped for
preliminary screening with Eurofins. This brings the total number of unique compounds in
the library to over 140.
5 high priority compounds have been shipped to the USA for evaluation with specialist
neuroscience CRO, PsychoGenics and additional metabolic studies have commenced with
an Australian CRO to help determine the metabolic half-life of a priority set of compounds.
This announcement has been approved and authorised for release by the CEO of Emyria.
FOR FURTHER INFORMATION
Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com
Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com
Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au
UPCOMING DRUG DEVELOPMENT MILESTONES
DRUG DEVELOPMENT
NEW DRUG DISCOVERY
CLINICAL PROGRAMS
Ultra-Pure cannabinoid delivery platform
PRE-CLINICAL PROGRAM
MDMA-like analogues
EMD-RX5 “direct-to-consumer”
EMD-RX7 “prescription medicine”
MDMA-like drug development
Formulation optimisation
Formulation optimisation
Continuous creation & screening
Phase 1 study
Phase 1
First patent family filed
Ethics approved for Phase 3
Pre-IND (FDA)
US-focussed preclinical program
Phase 3 commencement
Pivotal trials
Metabolic studies
Regulatory submission
Preclinical assays (multiple animal models)
Commercial strategy Australia
Human cell line assays
Commercial strategy Europe
Advanced assay development
Commercial strategy USA
Lead selection
Phase 1 trials
ABOUT EMYRIA | emyria.com
Global commercial strategy
Emyria Limited is a clinical drug development and care delivery company focused on accelerating
drug development and improving patient outcomes in neuroscience and mental health via:
●
Drug Development: Emyria has developed an Ultra-Pure cannabinoid platform that can
support the registration of multiple proprietary dose forms. Emyria’s first dose form,
EMD-RX5 is in Phase 3 trials
●
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest
libraries of MDMA-like compounds with partner, the University of Western Australia.
●
Proprietary Real-World Data (RWD): Emyria gathers ethically-sourced data with patients
cared for at Emyria’s own specialist clinical service (Emerald Clinics).
Emyria RWD can help support drug development and care model improvement.
EMYRIA’S
INTERACTIVE
INVESTOR
HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates by
asking questions and comments, which our team can respond to where possible.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release
about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and
other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including: the Company’s ability to
successfully develop its product candidates and timely complete its planned clinical programs and the
Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking
statements included in this press release represents the Company’s views as of the date hereof. The Company
anticipates that subsequent events and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
Share your feedback
Discover